Analytical Data
-
基因名
VSIG8
- Application
-
生物活性
Measured by its ability to chemoattract Jurkat human T-lymphocyte leukemia cells. The ED50 this effect is 0.7887 μg/ml, corresponding to a specific activity is 1267.91 units/mg. Measured by its ability to chemoattract Jurkat human T-lymphocyte leukemia cells. The ED50 this effect is 0.7887 μg/mL, corresponding to a specific activity is 1267.91 units/mg.
-
别名
V-set and immunoglobulin domain-containing protein 8; Vsig8
-
种属
Mouse
-
表达系统
HEK293
-
标签
C-6*His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q6P3A4-1
-
表达区间
V22-G262
-
氨基酸序列
VRINGDGQEVMYLAEGDNVRLGCPYLLDPEDLGTNSLDIEWMQVNSEPSHRENVFLTYQDKRIGHGNLPHLQQRVRFAASDPSQYDASINLMNLQVSDTATYECRVKKTTMATRKVIVTVQARPAVPMCWTEGHMSKGNDVVLKCFANGGSQPLSYKWAKISGHSHPYRAGAYHSQHSFHSELSYQESFHSTINQGLGNGDLLLKGINADDDGLYQCTVANHVGYSVCVVEVKVSDSQRVG
-
蛋白长度
Extracellular Domain
-
分子量
27 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TREM-2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor predominantly expressed on myeloid cells, notably microglia in the central nervous system. Its significance has surged in recent years due to its association with neurodegenerative diseases, particularly Alzheimer's disease. Genetic variants of TREM-2 have been linked to an increased risk of Alzheimer's, highlighting its role in microglial activation and immune response in the brain. Research has revealed that TREM-2 is crucial for the maintenance of microglial homeostasis and functions, influencing inflammatory responses and phagocytic activity. The interest in TREM-2 recombinant protein lies in its potential therapeutic applications. By understanding the mechanisms of TREM-2 signaling and its interactions with ligands, researchers are investigating how modulation of TREM-2 activity could enhance microglial function, potentially leading to improved outcomes in neurodegenerative conditions. Furthermore, recombinant TREM-2 protein can be used as a tool for studying its role in cellular pathways and for probing its function in immune regulation. Overall, the ongoing research into TREM-2 not only aims to elucidate its biological significance but also seeks to pave the way for innovative therapeutic strategies targeting neuroinflammation and neurodegeneration.
